In 2021, a specific semaglutide product called Wegovy was approved by the FDA for chronic weight management in adults struggling with obesity or being overweight
Practically, that means IGF-1 LR3 is generally avoided in anyone with a personal or family history that raises cancer concern and it's one more reason this is a medical decision, screened by a provider, not a purchase you make on your own
*Pooyandjoo 2016 study: effects observed in a 4 to 8-week course, variable depending on individuals and context (caloric deficit, physical activity)
Despite the high prevalence of CUD and its negative consequences, there are currently no FDA-approved medications
6.5% in non-GLP-1 households
"Theyre still looking at the science, Kennedy said